BioScience Laboratories has obtained seven clinical isolates of Carbapenem-Resistant (CR) Klebsiella pneumoniae and Escherichia coli. These organisms provide a strong model for predicting a product's efficacy against superbugs such as the New Delhi metallo-a-lactamase 1 (NDM-1) strain that has aroused recent worldwide concern. Carbapenems are historically used as a last resort for fighting bacterial infections, particularly versus multidrug-resistant Gram-negative species.
The five isolates of CR-Klebsiella pneumoniae and two isolates of CR-Escherichia coli are being used by BioScience Laboratories microbiologists to test products for their in-vitro efficacy as topical antimicrobials or hard-surface disinfectants to provide data predictive of a product's efficacy versus the New Delhi metallo-a-lactamase 1 (NDM-1) strain.
BioScience Laboratories, Inc. was founded in 1991 in Bozeman, Mont., to provide antimicrobial product testing and result interpretation grounded in science.